Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q1 2022 · 10-Q
Revenue$3.58M$3.58M+723.7% vs Q1 2021 Net Income-$50.27M-$50.27MN/M vs Q1 2021 EPS Diluted-$0.05-$0.05N/M vs Q1 2021 Operating Income-$49,981,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Free Cash Flowderived-$61,515,000N/M Margins · derivedOperating margin-1398.1%+7332.1 pt vs Q1 2021
Net margin-1406.0%+7295.1 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end